Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Launches Second CRT-P Pacemaker In Japan

This article was originally published in PharmAsia News

Executive Summary

Medtronic launched Consulta cardiac resynchronization therapy pacemaker in Japan, after the Minneapolis-based firm launched Syncra CRT-P system in March

Medtronic launched Consulta cardiac resynchronization therapy pacemaker in Japan, after the Minneapolis-based firm launched Syncra CRT-P system in March.

Consulta is the first CRT-P that includes Medtronic's exclusive OptiVol fluid status monitoring, which identifies patients at risk for worsening heart failure before symptoms develop. The launches expanded the products that have access to Medtronic Carelink network, a remote monitoring service connecting patients with clinicians. Now the lineup includes pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and CRT-Ps. (Click here for more - Japanese language)

"Medtronic Launches Pacemaker With Monitoring And Diagnostic Functions" - Chemical Daily (9/20/2011)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC079098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel